Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 12, 2014, Pages 3531-3543

  Comber, Joseph D ^a   Karabudak, Aykan ^a   Huang, Xiaofang ^a   Piazza, Paolo A ^b   Marques, Ernesto T A ^b   Philip, Ramila ^a  

^a Immunotope Inc   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

CTLs; Dengue virus; Immunoproteomics; MHC class I; Peptide vaccine

Indexed keywords

ALANYLMETHIONYLLEUCYLCYSTEINYLISOLEUCYLPROLYLASPARAGINYLALANYLISOLEUCYLISOLEUCINE; ALANYLPHENYLALANYLISOLEUCYLALANYLPHENYLALANYLVALYLARGINYLPHENYLALANINE; GAMMA INTERFERON; GRANZYME; GRANZYME B; HLA A2 ANTIGEN; HLA A24 ANTIGEN; LEUCYLLEUCYLCYSTEINYLVALYLPROLYLASPARAGINYLISOLEUCYLMETHIONYLISOLEUCINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHIONYLISOLEUCYLISOLEUCYLVALYLASPARTYLGLUTAMYLALANYLHISTIDYLPHENYLALANINE; PERFORIN; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; DENGUE VACCINE; EPITOPE;

ADULT; AMINO ACID SEQUENCE; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; CYTOKINE RELEASE; DENGUE; DENGUE VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LYMPHOCYTE SUBPOPULATION; MASS SPECTROMETRY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRE T LYMPHOCYTE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEOMICS; SEROTYPE; T LYMPHOCYTE ACTIVATION; UPREGULATION; HEPG2 CELL LINE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; TANDEM MASS SPECTROMETRY;

CD8-POSITIVE T-LYMPHOCYTES; DENGUE VACCINES; DENGUE VIRUS; EPITOPES, T-LYMPHOCYTE; HEP G2 CELLS; HLA-A2 ANTIGEN; HLA-A24 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; TANDEM MASS SPECTROMETRY;

EID: 84922575258     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.980210     Document Type: Article

References (53)

1. Weaver SC, Vasilakis N. Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease. Infect Genet Evol 2009; 9:523-40; PMID:19460319; http://dx.doi.org/10.1016/j.meegid.2009.02.003
2. Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine 2011; 29:7221-8; PMID:21781999; http://dx.doi.org/10.1016/j.vaccine.2011.07.022
3. Yacoub S, Mongkolsapaya J, Screaton G. The pathogenesis of dengue. Curr Opin Infect Dis 2013; 26:284-9; PMID:23449140; http://dx.doi.org/10.1097/QCO.0b013e32835fb938
4. Malavige GN, Ogg GS. T cell responses in dengue viral infections. J Clin Virol 2013; 58:605-11; PMID:24220605; http://dx.doi.org/10.1016/j.jcv.2013. 10.023
5. Weiskopf D, Sette A. T-cell immunity to infection with dengue virus in humans. Front Immunol 2014; 5:93; PMID:24639680; http://dx.doi.org/10.3389/fimmu. 2014.00093
6. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh Oet al. The global distribution and burden of dengue. Nature 2013; 496:504-7; PMID:23563266; http://dx.doi.org/10.1038/nature12060
7. Mathew A, Rothman AL. Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol Rev 2008; 225:300-13; PMID:18837790; http://dx.doi.org/10.1111/j.1600-065X.2008.00678.x
8. Bukowski JF, Kurane I, Lai CJ, Bray M, Falgout B, Ennis FA. Dengue virus-specific cross-reactive CD8C human cytotoxic T lymphocytes. J Virol 1989; 63:5086-91; PMID:2511337
9. Simmons CP, Dong T, Chau NV, Dung NT, Chau TN, Thao le TT, Hien TT, Rowland-Jones S, Farrar J. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol 2005; 79:5665-75; PMID:15827181; http://dx.doi.org/10.1128/JVI.79.9.5665-5675.2005
10. Nascimento EJ, Mailliard RB, Khan AM, Sidney J, Sette A, Guzman N, Paulaitis M, de Melo AB, Cordeiro MT, Gil LV, et al. Identification of conserved and HLA promiscuous DENV3 T-cell epitopes. PLoS Negl Trop Dis 2013; 7:e2497; PMID:24130917; http://dx.doi.org/10.1371/journal.pntd.0002497
11. de Melo AB, Nascimento EJ, Braga-Neto U, Dhalia R, Silva AM, Oelke M, Schneck JP, Sidney J, Sette A, Montenegro SM, et al. T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and-II binding motifs. PLoS Negl Trop Dis 2013; 7:e1938.
12. Piazza P, Campbell D, Marques E, Hildebrand WH, Buchli R, Mailliard R, Rinaldo CR. Dengue virus infected human dendritic cells reveal hierarchies of naturally expressed novel NS3 CD8 T cell epitopes. Clin Exp Immunol 2014; PMID:24816171
13. Mathew A, Kurane I, Rothman AL, Zeng LL, Brinton MA, Ennis FA. Dominant recognition by human CD8C cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J Clin Invest 1996; 98:1684-91; PMID:8833919; http://dx.doi.org/10.1172/JCI118964
14. Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P, Libraty DH, Gibbons R, Rothman AL. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 2011; 203:1282-91; PMID:21335561; http://dx.doi.org/10.1093/infdis/jir012
15. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, Peters B, Prestwood TR, Sette A, Shresta S. A protective role for dengue virus-specific CD8C T cells. J Immunol 2009; 182:4865-73; PMID:19342665; http://dx.doi.org/10.4049/jimmunol.0801974
16. Gil L, Lopez C, Blanco A, Lazo L, Martin J, Valdes I, Romero Y, Figueroa Y, Guillen G, Hermida L. The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol 2009; 22:23-30; PMID:19210225; http://dx.doi.org/10.1089/vim.2008.0063
17. Testa JS, Shetty V, Sinnathamby G, Nickens Z, Hafner J, Kamal S, Zhang X, Jett M, Philip R. Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for crossserotype reactive T-cell response. J Infect Dis 2012; 205:647-55; PMID:22246683; http://dx.doi.org/10.1093/infdis/jir814
18. Lund O, Nascimento EJ, MacielM, Jr, NielsenM, Larsen MV, Lundegaard C, HarndahlM, Lamberth K, Buus S, Salmon J, et al. Human leukocyte antigen (HLA) class I restricted epitope discovery in yellow fewer and dengue viruses: importance of HLA binding strength. PLoS One 2011; 6:e26494; PMID:22039500; http://dx.doi.org/10.1371/journal.pone.0026494
19. Wan SW, Lin CF, Wang S, Chen YH, Yeh TM, Liu HS, Anderson R, Lin YS. Current progress in dengue vaccines. J Biomed Sci 2013; 20:37; PMID:23758699; http://dx.doi.org/10.1186/1423-0127-20-37
20. Johnson BW, Chambers TV, Crabtree MB, Bhatt TR, Guirakhoo F, Monath TP, Miller BR. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am J Trop Med Hyg 2002; 67:260-5; PMID:12408664
21. Vazquez S, Guzman MG, Guillen G, Chinea G, Perez AB, Pupo M, Rodriguez R, Reyes O, Garay HE, Delgado I, et al. Immune response to synthetic peptides of dengue prM protein. Vaccine 2002; 20:1823-30; PMID:11906771; http://dx.doi.org/10.1016/S0264-410X(01)00515-1
22. de Melo AB, Nascimento EJ, Braga-Neto U, Dhalia R, Silva AM, Oelke M, Schneck JP, Sidney J, Sette A, Montenegro SM, et al. T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and-II binding motifs. PLoS Negl Trop Dis; 7:e1938; PMID: 23383350; http://dx.doi.org/10.1371/journal.pntd. 0001938
23. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002; 298:146-59; PMID:12093182; http://dx.doi.org/10.1006/viro. 2002.1462
24. Dayan GH, Garbes P, Noriega F, Izoton de Sadovsky AD, Rodrigues PM, Giuberti C, Dietze R. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil. Am J Trop Med Hyg 2013 89:1058-65; PMID:24189367; http://dx.doi.org/10.4269/ajtmh. 13-0304
25. Lindow JC, Durbin AP, Whitehead SS, Pierce KK, Carmolli MP, Kirkpatrick BD. Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. Vaccine 2013; 31:3347-52; PMID:23735680; http://dx.doi.org/10.1016/j.vaccine.2013.05.075
26. Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest 2004; 113:946-51; PMID:15057297; http://dx.doi.org/10.1172/JCI21512
27. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol 2008; 9:1; PMID:18211710; http://dx.doi.org/10.1186/1471-2172-9-1
28. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, Broadwater A, Kolla RV, De Silva AD, de Silva AM, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8C T cells. Proc Natl Acad Sci U S A; 110:E2046-53; PMID:23580623
29. Khan AM, Miotto O, Nascimento EJ, Srinivasan KN, Heiny AT, Zhang GL, Marques ET, Tan TW, Brusic V, Salmon J, et al. Conservation and variability of dengue virus proteins: implications for vaccine design. PLoS Negl Trop Dis 2008; 2:e272; PMID:18698358; http://dx.doi.org/10.1371/journal.pntd.0000272
30. Olsen LR, ZhangGL, KeskinDB, Reinherz EL, Brusic V. Conservation analysis of dengue virus T-cell epitopebased vaccine candidates using Peptide block entropy. Front Immunol 2011; 2:69; PMID:22566858; http://dx.doi.org/10.3389/fimmu.2011.00069
31. Shetty V, Nickens Z, Testa J, Hafner J, Sinnathamby G, Philip R. Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cells. J Proteomics 2012; 75:3270-90; PMID:22504797; http://dx.doi.org/10.1016/j.jprot.2012.03.044
32. Shetty V, Sinnathamby G, Nickens Z, Shah P, Hafner J, Mariello L, Kamal S, Vlahovic G, Lyerly HK, Morse MA, et al. MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. J Proteomics 2011; 74:728-43; PMID:21362506; http://dx.doi.org/10.1016/j.jprot.2011.02.020
33. Testa JS, Shetty V, Hafner J, Nickens Z, Kamal S, Sinnathamby G, Philip R. MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response. PLoS One 2012; 7:e48484; PMID:23144892; http://dx.doi.org/10.1371/journal.pone.0048484
34. Guabiraba R, Ryffel B. Dengue virus infection: current concepts in immune mechanisms and lessons from murine models. Immunology 2014; 141:143-56; PMID:24182427; http://dx.doi.org/10.1111/imm. 12188
35. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998; 11:480-96; PMID:9665979
36. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA. Sensitive and viable identification of antigen-specific CD8C T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78; PMID:14580882; http://dx.doi.org/10.1016/S0022-1759(03)00265-5
37. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8C cells recognizing HER2/neu vaccine peptides. Breast Cancer Res Treat 2005; 92:85-93; PMID:15980996; http://dx.doi.org/10.1007/s10549-005-0988-1
38. Parmigiani A, Alcaide ML, Freguja R, Pallikkuth S, Frasca D, Fischl MA, Pahwa S. Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation. PLoS One 2013; 8: e79816; PMID:24236161; http://dx.doi.org/10.1371/journal.pone.0079816
39. Nieminen JK, Niemi M, Sipponen T, Salo HM, Klemetti P, Farkkila M, Vakkila J, Vaarala O. Dendritic cells from Crohn's disease patients show aberrant STAT1 and STAT3 signaling. PLoS One 2013; 8: e70738; PMID:23950992; http://dx.doi.org/10.1371/journal.pone.0070738
40. Rey FA. Dengue virus envelope glycoprotein structure: new insight into its interactions during viral entry. Proc Natl Acad Sci U S A 2003; 100:6899-901; PMID:12782795; http://dx.doi.org/10.1073/pnas. 1332695100
41. Rosendahl Huber S, van Beek J, de Jonge J, Luytjes W, van Baarle D. T cell responses to viral infections-opportunities for peptide vaccination. Front Immunol 2014; 5:171; PMID:24795718; http://dx.doi.org/10.3389/fimmu.2014.00171
42. Comber JD, Philip R. MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. Ther Adv Vaccines 2014; 2:77-89; PMID:24790732; http://dx.doi.org/10.1177/2051013614525375
43. Testa JS, Philip R. Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications. Future Virol 2012; 7:1077-88; PMID:23630544; http://dx.doi.org/10.2217/fvl.12.108
44. Gulukota K, DeLisi C. HLA allele selection for designing peptide vaccines. Genet Anal 1996; 13:81-6; PMID:8931995; http://dx.doi.org/10.1016/1050-3862(95)00156-5
45. Slingluff CL, Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007; 13:6386-95; PMID:17975151; http://dx.doi.org/10.1158/1078-0432.CCR-07-0486
46. Slingluff CL, Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J 2011; 17:343-50; PMID:21952285; http://dx.doi.org/10.1097/PPO.0b013e318233e5b2
47. Morse MA, Secord AA, Blackwell K, Hobeika AC, Sinnathamby G, Osada T, Hafner J, Philip M, Clay TM, Lyerly HK, et al. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin Cancer Res 2011; 17:3408-19; PMID:21300761; http://dx.doi.org/10.1158/1078-0432.CCR-10-2614
48. de Melo AB, da Silva Mda P, Magalhaes MC, Gonzales Gil LH, Freese de Carvalho EM, Braga-Neto UM, Bertani GR, Marques ET, Jr, Cordeiro MT. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 2011; 85:739-47; PMID:21976581; http://dx.doi.org/10.4269/ajtmh. 2011.10-0496
49. Cordeiro MT, Silva AM, Brito CA, Nascimento EJ, Magalhaes MC, Guimaraes GF, Lucena-Silva N, de Carvalho EM, Marques ET, Jr. Characterization of a dengue patient cohort in Recife, Brazil. Am J Trop Med Hyg 2007; 77:1128-34; PMID:18165535
50. Cordeiro MT, Braga-Neto U, Nogueira RM, Marques ET, Jr. Reliable classifier to differentiate primary and secondary acute dengue infection based on IgG ELISA. PLoS One 2009; 4:e4945; PMID:19340301; http://dx.doi.org/10.1371/journal.pone.0004945
51. Xavier Eurico de Alencar L, de Mendonca Braga-Neto U, Jose Moura do Nascimento E, Tenorio Cordeiro M, Maria Silva A, Alexandre Antunes de Brito C, da Silva Mda P, Gil LH, Montenegro SM, Marques ET, Jr. HLA-B ∗44 is associated with dengue severity caused by DENV-3 in a Brazilian population. J Trop Med 2013; 2013:648475; PMID:23818909; http://dx.doi.org/10.1155/2013/648475
52. Testa JS, Shetty V, Hafner J, Nickens Z, Kamal S, Sinnathamby G, Philip R. MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response. PLoS One; 7:e48484; 23144892; http://dx.doi.org/10.1371/journal.pone.0048484
53. Testa JS, Shetty V, Sinnathamby G, Nickens Z, Hafner J, Kamal S, Zhang X, Jett M, Philip R. Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for crossserotype reactive T-cell response. J Infect Dis; 205:647-55; PMID:22246683; http://dx.doi.org/10.1093/infdis/jir814